In this video, Fool health-care analyst David Williamson discusses Discovery Labs (NASDAQ: DSCO), as it struggles with yet another delay to its drug Surfaxin. Shares are down 15% on news that the FDA has requested Surfaxin product specifications and a new analytical chemistry method. It took the company an unbelievable five attempts to finally get this drug approved a year ago. David tells investors when they might expect the delays to end, and what the key things to watch with Discovery Labs will be in the meantime, as the company continues to lose out on sales and burn cash.
Discovering Yet Another Drug Delay
By Dave Williamson
-
Apr 15, 2013 at 6:46PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This company is king when it comes to drug delays.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.